News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News Zealand Pharma rakes in $1bn in funding for obesity drugs Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
